NEW YORK, Dec. 27 (GenomeWeb News) - Affymetrix granted Vita Genomics non-exclusive access to its microarray technology to develop and market in vitro diagnostics, the companies announced jointly yesterday.
Shanghai GeneCore BioTechnologies, a fully owned subsidiary of Vita Genomics, licensed the technology under the "Powered by Affymetrix" program. The program allows companies to license Affymetrix's microarray products such as the GeneChip System 3000Dx.
Vita Genomics will develop in vitro tests to detect alpha interferon treatment response in patients with HBV and HCV as well as for early onset and allergic asthma in infants and young children.
Vita Genomics will incorporate Affymetrix's arrays into its molecular diagnostic assays.
Financial details were not disclosed.